ReviewLeukemia & lymphoma2011
T-cell and natural killer-cell large granular lymphocyte leukemia neoplasias.
Review in Leukemia & lymphoma, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 43 citations in OpenAlex.
- A case report of CD4Annals of hematology · 2026Article
- Chidamide-maintained long-term clinical remission with persistent T-Cell clone in refractory T-LGL leukemia-associated pure red cell aplasia: A six-year follow-up.Leukemia research reports · 2026Article
- Expansion of large granular lymphocytes after autologous hematopoietic stem cell transplantation.International journal of hematology · 2023Article
- Large granular lymphocytic leukemia cured by allogeneic stem cell transplant: a case report.Journal of medical case reports · 2022Article
- Large Granular Lymphocytic Leukemia: Current State of Diagnosis, Pathogenesis and Treatment.Current oncology reports · 2022Review
- Article
- Review
- Large Granular Lymphocytic Leukemia: A Report of Response to Rituximab.Case reports in hematology · 2017Article
- Atypical aleukemic presentation of large granular lymphocytic leukemia: a case report.OncoTargets and therapy · 2017Article
- The pathogenesis and treatment of large granular lymphocyte leukemia.Blood reviews · 2014Review
- CD4(-)/CD8(-) variant of T-cell large granular lymphocytic leukemia or hepatosplenic T-cell lymphoma: a clinicopathologic dilemma.Clinical lymphoma, myeloma & leukemia · 2013Article
- Unraveling the molecular events leading to the genesis of large granular lymphocytic leukemia reveals a new treatment strategy.Haematologica · 2013Article
- MicroRNA regulation of natural killer cells.Frontiers in immunology · 2013Article
- Diagnosis of large granular lymphocytic leukemia in a patient previously treated for acute myeloblastic leukemia.Hematology reports · 2013Article
- Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets.Future oncology (London, England) · 2012Review
- Natural killer cell regulation by microRNAs in health and disease.Journal of biomedicine & biotechnology · 2012Review
- Management of T-cell malignancies: Bench-to-bedside targeting of epigenetic biology.CA: a cancer journal for cliniciansReview
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Large granular lymphocyte (LGL) leukemia is a rare disorder of cytotoxic lymphocytes. LGL cells play an integral role in the immune system and are divided into two major lineages of CD3(-)natural killer (NK) cells and CD3(+) T cells that circulate throughout the blood in search of infected cells, in which they will make contact through a receptor ligand and induce cell death. LGL cells are also programmed to undergo apoptosis after contact with an infected target cell; however, they continue to survive in individuals with LGL leukemia. This unchecked proliferation and cytotoxicity of LGLs in patients results in autoimmunity or malignancy. Rheumatoid arthritis is the most common autoimmune condition seen in individuals with LGL leukemia; however, LGL leukemia is associated with a wide spectrum of other autoimmune diseases. Patients may also suffer from other hematological conditions including hemolytic anemia, pure red cell aplasia, and neutropenia, which lead to recurrent bacterial infections. Currently, the only established treatment involves a low dose of an immunosuppressive regimen with methotrexate, in which 40-50% of patients are either resistant or do not respond. In order to establish new therapeutics it is important to understand the current state of LGL leukemia both in the clinic and in basic research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.